PortfoliosLab logo
PortfoliosLab logo
Tools
Performance Analysis
Portfolio Analysis
Factor Model
Portfolios
Lazy PortfoliosUser Portfolios
Discussions
EMX vs. PFE
Performance
Risk-Adjusted Performance
Dividends
Drawdowns
Volatility
Financials

Correlation

The correlation between EMX and PFE is 0.05, which is considered to be low. This implies their price changes are not closely related. A low correlation is generally favorable for portfolio diversification, as it helps to reduce overall risk by spreading it across multiple assets with different performance patterns.


-0.50.00.51.00.0

Performance

EMX vs. PFE - Performance Comparison

The chart below illustrates the hypothetical performance of a $10,000 investment in EMX Royalty Corporation (EMX) and Pfizer Inc. (PFE). The values are adjusted to include any dividend payments, if applicable.

-15.00%-10.00%-5.00%0.00%5.00%10.00%15.00%20.00%SeptemberOctoberNovemberDecember2025February
10.65%
-7.81%
EMX
PFE

Key characteristics

Sharpe Ratio

EMX:

0.65

PFE:

-0.06

Sortino Ratio

EMX:

1.25

PFE:

0.08

Omega Ratio

EMX:

1.14

PFE:

1.01

Calmar Ratio

EMX:

0.41

PFE:

-0.03

Martin Ratio

EMX:

1.78

PFE:

-0.16

Ulcer Index

EMX:

13.89%

PFE:

9.44%

Daily Std Dev

EMX:

37.69%

PFE:

23.19%

Max Drawdown

EMX:

-90.61%

PFE:

-54.82%

Current Drawdown

EMX:

-49.81%

PFE:

-51.26%

Fundamentals

Market Cap

EMX:

$198.67M

PFE:

$144.68B

EPS

EMX:

-$0.02

PFE:

$1.41

PEG Ratio

EMX:

0.00

PFE:

0.18

Total Revenue (TTM)

EMX:

$16.84M

PFE:

$45.86B

Gross Profit (TTM)

EMX:

$6.38M

PFE:

$29.87B

EBITDA (TTM)

EMX:

$4.51M

PFE:

$15.61B

Returns By Period

In the year-to-date period, EMX achieves a 8.09% return, which is significantly higher than PFE's -1.76% return. Over the past 10 years, EMX has outperformed PFE with an annualized return of 9.48%, while PFE has yielded a comparatively lower 1.57% annualized return.


EMX

YTD

8.09%

1M

8.72%

6M

10.65%

1Y

27.21%

5Y*

-0.73%

10Y*

9.48%

PFE

YTD

-1.76%

1M

-1.31%

6M

-7.81%

1Y

0.51%

5Y*

-1.57%

10Y*

1.57%

*Annualized

Compare stocks, funds, or ETFs

Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.


Risk-Adjusted Performance

EMX vs. PFE — Risk-Adjusted Performance Rank

Compare risk-adjusted metric ranks to identify better-performing investments over the past 12 months.

EMX
The Risk-Adjusted Performance Rank of EMX is 6464
Overall Rank
The Sharpe Ratio Rank of EMX is 6868
Sharpe Ratio Rank
The Sortino Ratio Rank of EMX is 6464
Sortino Ratio Rank
The Omega Ratio Rank of EMX is 6060
Omega Ratio Rank
The Calmar Ratio Rank of EMX is 6464
Calmar Ratio Rank
The Martin Ratio Rank of EMX is 6464
Martin Ratio Rank

PFE
The Risk-Adjusted Performance Rank of PFE is 3939
Overall Rank
The Sharpe Ratio Rank of PFE is 4343
Sharpe Ratio Rank
The Sortino Ratio Rank of PFE is 3434
Sortino Ratio Rank
The Omega Ratio Rank of PFE is 3333
Omega Ratio Rank
The Calmar Ratio Rank of PFE is 4444
Calmar Ratio Rank
The Martin Ratio Rank of PFE is 4242
Martin Ratio Rank
The risk-adjusted ranks indicate the investment's position relative to the market. A rank closer to 100 signifies top-performing investments, while a rank closer to 0 might suggest underperformance, based on the selected ratio. The values are calculated based on the past 12 months of returns.

EMX vs. PFE - Risk-Adjusted Performance Comparison

This table presents a comparison of risk-adjusted performance metrics for EMX Royalty Corporation (EMX) and Pfizer Inc. (PFE). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.


Sharpe ratio
The chart of Sharpe ratio for EMX, currently valued at 0.65, compared to the broader market-2.000.002.004.000.65-0.06
The chart of Sortino ratio for EMX, currently valued at 1.25, compared to the broader market-6.00-4.00-2.000.002.004.006.001.250.08
The chart of Omega ratio for EMX, currently valued at 1.14, compared to the broader market0.501.001.502.001.141.01
The chart of Calmar ratio for EMX, currently valued at 0.41, compared to the broader market0.002.004.006.000.41-0.03
The chart of Martin ratio for EMX, currently valued at 1.78, compared to the broader market0.0010.0020.0030.001.78-0.16
EMX
PFE

The current EMX Sharpe Ratio is 0.65, which is higher than the PFE Sharpe Ratio of -0.06. The chart below compares the historical Sharpe Ratios of EMX and PFE, offering insights into how both investments have performed under varying market conditions. These values are calculated using daily returns over the previous 12 months.


Rolling 12-month Sharpe Ratio-0.500.000.50SeptemberOctoberNovemberDecember2025February
0.65
-0.06
EMX
PFE

Dividends

EMX vs. PFE - Dividend Comparison

EMX has not paid dividends to shareholders, while PFE's dividend yield for the trailing twelve months is around 6.59%.


TTM20242023202220212020201920182017201620152014
EMX
EMX Royalty Corporation
0.00%0.00%0.00%0.00%0.00%0.00%0.00%0.00%0.00%0.00%0.00%0.00%
PFE
Pfizer Inc.
6.59%6.33%5.70%3.12%2.64%3.92%3.68%3.12%3.54%3.70%3.48%3.34%

Drawdowns

EMX vs. PFE - Drawdown Comparison

The maximum EMX drawdown since its inception was -90.61%, which is greater than PFE's maximum drawdown of -54.82%. Use the drawdown chart below to compare losses from any high point for EMX and PFE. For additional features, visit the drawdowns tool.


-56.00%-54.00%-52.00%-50.00%-48.00%-46.00%-44.00%SeptemberOctoberNovemberDecember2025February
-49.60%
-51.26%
EMX
PFE

Volatility

EMX vs. PFE - Volatility Comparison

EMX Royalty Corporation (EMX) has a higher volatility of 7.71% compared to Pfizer Inc. (PFE) at 6.50%. This indicates that EMX's price experiences larger fluctuations and is considered to be riskier than PFE based on this measure. The chart below showcases a comparison of their rolling one-month volatility.


4.00%6.00%8.00%10.00%12.00%14.00%SeptemberOctoberNovemberDecember2025February
7.71%
6.50%
EMX
PFE

Financials

EMX vs. PFE - Financials Comparison

This section allows you to compare key financial metrics between EMX Royalty Corporation and Pfizer Inc.. You can select fields from income statements, balance sheets, and cash flow statements to easily visualize and compare the financial health of both companies.


Quarterly
Annual

Total Revenue: Total amount of money received from sales and other business activities


Values in USD except per share items
PortfoliosLab logo
Performance Analysis
Portfolio AnalysisPortfolio PerformanceStock ComparisonSharpe RatioMartin RatioTreynor RatioSortino RatioOmega RatioCalmar RatioSummers Ratio
Community
Discussions


Disclaimer

The information contained herein does not constitute investment advice and made available for educational purposes only. Prices and returns on equities are listed without consideration of fees, commissions, taxes, penalties, or interest payable due to purchasing, holding, or selling.

Copyright © 2025 PortfoliosLab